The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats
- PMID: 15087716
- DOI: 10.1097/00004647-200404000-00012
The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats
Abstract
The goal of the present study was to test the impact of administration time of the angiotensin II type 1-receptor blocker candesartan on cerebral blood flow (CBF), infarct size, and neuroscore in transient cerebral ischemia. Therefore, 1-hour middle cerebral artery occlusion (MCAO) was followed by reperfusion. Rats received 0.5-mg/kg candesartan intravenously 2 hours before MCAO (pretreatment), 24 hours after MCAO, every 24 hours after MCAO, or 2 hours before and every 24 hours after MCAO. Infarct size (mm3) and a neuroscore at day 7 were compared with controls. CBF was quantified by radiolabeled microspheres and laser-Doppler flowmetry. Compared with controls (95 +/- 8), infarct size in candesartan-treated groups was smaller (59 +/- 5, 68 +/- 10, 28 +/- 3, and 15 +/- 3, respectively; P<0.05). Although there was no difference in neuroscore between pretreatment and controls (1.55 +/- 0.18, 1.80 +/- 0.13), other treatment regimens resulted in improved neuroscores (1.33 +/- 0.16, 1.11 +/- 0.11, 0.73 +/- 0.15; P<0.05). CBF in pretreated animals at 0.5 hours after MCAO was significantly higher than in controls (0.58 +/- 0.09 mL x g(-1) x min(-1) and 44% +/- 7% of baseline compared with 0.49 +/- 0.06 mL x g(-1) x min(-1) and 37% +/- 6%, microspheres and laser-Doppler flowmetry; P<0.05). Thus, candesartan reduces infarct size even if administered only during reperfusion. Apart from pretreatment, other treatment regimens result in significantly improved neuroscores. In the acute phase of cerebral ischemia, candesartan increases CBF.
Similar articles
-
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.Neurosci Lett. 2006 Oct 2;406(1-2):92-6. doi: 10.1016/j.neulet.2006.07.022. Epub 2006 Aug 9. Neurosci Lett. 2006. PMID: 16901636
-
Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.Hypertens Res. 2009 Jul;32(7):548-53. doi: 10.1038/hr.2009.69. Epub 2009 May 8. Hypertens Res. 2009. PMID: 19424281
-
Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain.Brain Res. 2008 May 7;1208:225-33. doi: 10.1016/j.brainres.2008.02.032. Epub 2008 Mar 4. Brain Res. 2008. PMID: 18378216
-
Embracing Heterogeneity in The Multicenter Stroke Preclinical Assessment Network (SPAN) Trial.Stroke. 2023 Feb;54(2):620-631. doi: 10.1161/STROKEAHA.122.040638. Epub 2023 Jan 5. Stroke. 2023. PMID: 36601951 Free PMC article. Review.
-
Pharmacological strategies in the treatment of cerebral ischemia.Eur Neurol. 1995;35 Suppl 1:28-36. doi: 10.1159/000119496. Eur Neurol. 1995. PMID: 8529727 Review. No abstract available.
Cited by
-
The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation.J Cereb Blood Flow Metab. 2018 Dec;38(12):2129-2149. doi: 10.1177/0271678X18800589. Epub 2018 Sep 10. J Cereb Blood Flow Metab. 2018. PMID: 30198826 Free PMC article. Review.
-
CV-11974, angiotensin II type I receptor antagonist, reduces the severity of indomethacin-induced rat enteritis.Dig Dis Sci. 2008 Mar;53(3):657-63. doi: 10.1007/s10620-007-9931-0. Epub 2007 Sep 1. Dig Dis Sci. 2008. PMID: 17763956
-
Brain-Derived Neurotrophic Factor Knockdown Blocks the Angiogenic and Protective Effects of Angiotensin Modulation After Experimental Stroke.Mol Neurobiol. 2017 Jan;54(1):661-670. doi: 10.1007/s12035-015-9675-3. Epub 2016 Jan 12. Mol Neurobiol. 2017. PMID: 26758277 Free PMC article.
-
Estrogen prevents intestinal inflammation after trauma-hemorrhage via downregulation of angiotensin II and angiotensin II subtype I receptor.Am J Physiol Gastrointest Liver Physiol. 2008 Nov;295(5):G1131-7. doi: 10.1152/ajpgi.90443.2008. Epub 2008 Oct 2. Am J Physiol Gastrointest Liver Physiol. 2008. PMID: 18832446 Free PMC article.
-
Vascular plasticity in cerebrovascular disorders.J Cereb Blood Flow Metab. 2011 Jul;31(7):1554-71. doi: 10.1038/jcbfm.2011.70. Epub 2011 May 11. J Cereb Blood Flow Metab. 2011. PMID: 21559027 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous